We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Cubist Pharmaceuticals Enrolls First Subject in Phase 2 Trial for Therapy to Treat CDAD

News   Apr 09, 2010

 
Cubist Pharmaceuticals Enrolls First Subject in Phase 2 Trial for Therapy to Treat CDAD
 
 
 

RELATED ARTICLES

Early Benefit Assessment Exposes Weaknesses in the Development of New Drugs

News

More than half of the drugs that have entered the market in Germany since then have emerged from these assessments without any proven added benefit. In a new publication using the first 216 assessments, researchers examine the reasons for this sobering result and develop suggestions for improvements in drug development.

READ MORE

Larger, Earlier Drug Trials Needed to Fight Alzheimer's

News

There are currently no drugs that stop or inhibit Alzheimer's disease. Despite drug trials showing plaque reduction in the brain, the patients' cognitive function did not improve. Would the results be different if it were possible to design studies that intervene much earlier on in the disease, before cognition is affected?

READ MORE

Collagen Found to Be Effective in Wound Closure

News

Collagen powder is just as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures, according to a first-of-its-kind study.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE